DOP2016000047A - Compuestos y composiciones como inhibidores de la mek - Google Patents

Compuestos y composiciones como inhibidores de la mek

Info

Publication number
DOP2016000047A
DOP2016000047A DO2016000047A DO2016000047A DOP2016000047A DO P2016000047 A DOP2016000047 A DO P2016000047A DO 2016000047 A DO2016000047 A DO 2016000047A DO 2016000047 A DO2016000047 A DO 2016000047A DO P2016000047 A DOP2016000047 A DO P2016000047A
Authority
DO
Dominican Republic
Prior art keywords
compounds
compositions
mek
inhibitors
cerative
Prior art date
Application number
DO2016000047A
Other languages
English (en)
Inventor
Mark Gary Bock
Henrik Moebitz
Sunil Kumar Panigrahi
Ramulu Poddutoori
Susanta Samajdar
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of DOP2016000047A publication Critical patent/DOP2016000047A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCIÓN SE RELACIONA CON COMPUESTOS DE LA FÓRMULA I: EN LA CUAL N, R1, R2, R3A, R4 Y R5 SE DEFINEN EN EL RESUMEN DE LA INVENCIÓN; CAPAZ DE INHIBIR LA ACTIVIDAD DE MEK. LA INVENCIÓN PROPORCIONA ADEMÁS UN PROCEDIMIENTO PARA LA PREPARACIÓN DE COMPUESTOS DE LA INVENCIÓN, LAS PREPARACIONES FARMACÉUTICAS QUE COMPRENDEN TALES COMPUESTOS Y MÉTODOS DE USO DE TALES COMPUESTOS Y COMPOSICIONES EN EL MANEJO DE ENFERMEDADES HIPERPROLIFERATIVAS SIMILARES AL CÁNCER.
DO2016000047A 2013-08-14 2016-02-10 Compuestos y composiciones como inhibidores de la mek DOP2016000047A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2418DE2013 2013-08-14
IN1686DE2014 2014-06-24

Publications (1)

Publication Number Publication Date
DOP2016000047A true DOP2016000047A (es) 2016-08-31

Family

ID=51844790

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2016000047A DOP2016000047A (es) 2013-08-14 2016-02-10 Compuestos y composiciones como inhibidores de la mek

Country Status (33)

Country Link
US (3) US9227969B2 (es)
EP (1) EP3033343B1 (es)
JP (1) JP6473453B2 (es)
KR (1) KR102354208B1 (es)
CN (1) CN105473588B (es)
AP (1) AP2016008981A0 (es)
AU (1) AU2014307593C1 (es)
BR (1) BR112016001783B1 (es)
CA (1) CA2921300C (es)
CL (1) CL2016000150A1 (es)
CR (1) CR20160072A (es)
CU (1) CU20160020A7 (es)
DO (1) DOP2016000047A (es)
EA (1) EA029093B1 (es)
ES (1) ES2714718T3 (es)
GE (1) GEP201706725B (es)
HK (1) HK1219271A1 (es)
IL (1) IL243349A0 (es)
MX (1) MX359401B (es)
NI (1) NI201600014A (es)
PE (1) PE20160204A1 (es)
PH (1) PH12016500003A1 (es)
PL (1) PL3033343T3 (es)
PT (1) PT3033343T (es)
SG (1) SG11201510727VA (es)
SV (1) SV2016005153A (es)
TN (1) TN2015000574A1 (es)
TR (1) TR201902709T4 (es)
TW (1) TW201536782A (es)
UA (1) UA116566C2 (es)
UY (1) UY35704A (es)
WO (1) WO2015022662A1 (es)
ZA (1) ZA201509337B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
JP6783224B2 (ja) 2014-04-04 2020-11-11 デル マー ファーマシューティカルズ 肺の非小細胞癌腫及び卵巣癌を処置するためのジアンヒドロガラクチトール及びその類縁体又は誘導体の使用
HK1244274A1 (zh) 2015-01-30 2018-08-03 生物医学谷探索股份有限公司 C21h22ci2n4o2的晶型
CA3168216C (en) * 2015-01-30 2025-11-18 Biomed Valley Discoveries, Inc. CRYSTALIN MALONATE C21H22Cl2N4O2
RU2017139727A (ru) * 2015-06-15 2019-07-16 АСАНА БАЙОСАЙЕНСИЗ, ЭлЭлСи Гетероциклические ингибиторы erk1 и erk2 и их применение для лечения злокачественного новообразования
TWI674261B (zh) 2017-02-17 2019-10-11 美商英能腫瘤免疫股份有限公司 Nlrp3 調節劑
US20210380683A1 (en) * 2018-04-12 2021-12-09 The Methodist Hospital System Modulation of irf-4 and uses thereof
EP3942045A1 (en) 2019-03-21 2022-01-26 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
CN110141657B (zh) * 2019-05-17 2023-01-17 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 一种表皮生长因子脂质体及其制备方法
BR112022003514A2 (pt) 2019-09-16 2022-05-17 Novartis Ag Degradadores bifuncionais de brd9 e seus métodos de uso
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN115124524A (zh) * 2021-03-26 2022-09-30 浙江海正药业股份有限公司 三环类衍生物及其制备方法和用途
WO2022251193A1 (en) 2021-05-27 2022-12-01 Mirati Therapeutics, Inc. Combination therapies
JP2024529347A (ja) * 2021-07-14 2024-08-06 インサイト・コーポレイション Ｋｒａｓの阻害剤としての三環式化合物
EP4499623A2 (en) * 2022-03-24 2025-02-05 Biomed Valley Discoveries, Inc. Deuterated analogs of pyrrole inhibitors of erk, synthesis thereof and intermediates thereto
JP2025529185A (ja) * 2022-08-30 2025-09-04 パンネックス セラピューティクス インコーポレイテッド パネキシン－１調節剤及びパネキシン－１が関与する疾患の治療方法
CN117800964A (zh) * 2022-09-30 2024-04-02 四川大学 PI3K/m-TOR抑制剂及其应用
WO2025073765A1 (en) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH445129A (fr) 1964-04-29 1967-10-15 Nestle Sa Procédé pour la préparation de composés d'inclusion à poids moléculaire élevé
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US3453257A (en) 1967-02-13 1969-07-01 Corn Products Co Cyclodextrin with cationic properties
US3426011A (en) 1967-02-13 1969-02-04 Corn Products Co Cyclodextrins with anionic properties
US3453259A (en) 1967-03-22 1969-07-01 Corn Products Co Cyclodextrin polyol ethers and their oxidation products
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
ATE28864T1 (de) 1982-07-23 1987-08-15 Ici Plc Amide-derivate.
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
ZA848968B (en) 1983-11-18 1986-06-25 Riker Laboratories Inc 1h-imidazo(4,5-c)quinolines and 1h-imidazo(4,5-c)quinolin-4-amines
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
DK0385630T3 (da) 1989-02-27 1997-05-12 Riker Laboratories Inc 1H-imidazo(4,5-c)quinolin-4-aminer som antivirale midler
US5010099A (en) 1989-08-11 1991-04-23 Harbor Branch Oceanographic Institution, Inc. Discodermolide compounds, compositions containing same and method of preparation and use
GB8928281D0 (en) 1989-12-14 1990-02-21 Smith Kline French Lab Compounds
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5395855A (en) 1990-05-07 1995-03-07 Ciba-Geigy Corporation Hydrazones
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
TW225528B (es) 1992-04-03 1994-06-21 Ciba Geigy Ag
DK1975181T3 (da) 1992-10-28 2011-06-06 Genentech Inc Anvendelse af vaskulære endothelcelle-vækstfaktor-antagonister
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
IL115849A0 (en) 1994-11-03 1996-01-31 Merz & Co Gmbh & Co Tangential filtration preparation of liposomal drugs and liposome product thereof
DE69536015D1 (de) 1995-03-30 2009-12-10 Pfizer Prod Inc Chinazolinone Derivate
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
EP0836605B1 (en) 1995-07-06 2002-02-06 Novartis AG Pyrrolopyrimidines and processes for the preparation thereof
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
JP3370340B2 (ja) 1996-04-12 2003-01-27 ワーナー―ランバート・コンパニー チロシンキナーゼの不可逆的阻害剤
EP0907642B1 (en) 1996-06-24 2005-11-02 Pfizer Inc. Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
AU716610B2 (en) 1996-08-30 2000-03-02 Novartis Ag Method for producing epothilones, and intermediate products obtained during the production process
DE938597T1 (de) 1996-09-06 2000-03-09 Obducat Ab Verfahren für das anisotrope ätzen von strukturen in leitende materialien
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
AU4342997A (en) 1996-09-13 1998-04-02 Sugen, Inc. Use of quinazoline derivatives for the manufacture of a medicament in the reatment of hyperproliferative skin disorders
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
JP4274583B2 (ja) 1996-11-18 2009-06-10 ゲゼルシャフト・フュア・ビオテクノロギッシェ・フォルシュンク・ミット・ベシュレンクテル・ハフツング（ゲー・ベー・エフ） エポチロンｃ，ｄ，ｅ及びｆ、製造と薬剤
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
JP2002504540A (ja) 1998-02-25 2002-02-12 スローン−ケッタリング インスティトゥート フォア キャンサー リサーチ エポチロンの合成、その中間体およびそのアナログ
EP1107964B8 (en) 1998-08-11 2010-04-07 Novartis AG Isoquinoline derivatives with angiogenesis inhibiting activity
JP2000119271A (ja) * 1998-08-12 2000-04-25 Hokuriku Seiyaku Co Ltd １ｈ―イミダゾピリジン誘導体
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
KR100851418B1 (ko) 1998-11-20 2008-08-08 코산 바이오사이언시즈, 인코포레이티드 에포틸론 및 에포틸론 유도체의 생산을 위한 재조합 방법 및 물질
EP2016953A3 (en) 1998-12-22 2009-04-15 Genentech, Inc. Vascular endothelial cell growth factor antagonists and uses thereof
JP4673977B2 (ja) 1999-03-30 2011-04-20 ノバルティス アーゲー 炎症性疾患治療用フタラジン誘導体
WO2002016370A1 (en) 2000-08-22 2002-02-28 Hokuriku Seiyaku Co., Ltd. 1h-imidazopyridine derivatives
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
TWI238824B (en) 2001-05-14 2005-09-01 Novartis Ag 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
GB0211649D0 (en) 2002-05-21 2002-07-03 Novartis Ag Organic compounds
JP2004161662A (ja) 2002-11-13 2004-06-10 Abbott Japan Co Ltd １ｈ−イミダゾキノリン誘導体
CN1747953A (zh) * 2002-12-20 2006-03-15 3M创新有限公司 芳基/杂芳基取代的咪唑并喹啉
EP1590348A1 (en) * 2002-12-20 2005-11-02 3M Innovative Properties Company Aryl / hetaryl substituted imidazoquinolines
WO2004080398A2 (en) * 2003-03-07 2004-09-23 3M Innovative Properties Company 1-amino 1h-imidazoquinolines
BRPI0412236A (pt) 2003-07-02 2006-09-12 Hoffmann La Roche compostos, processo para a sua manufatura, composições farmacêuticas que compreendem os mesmos, método para o tratamento e/ou prevenção de enfermidades que são moduladas por agonistas ppar(delta) e/ou ppar(alfa), e utilização desses compostos
AR046845A1 (es) 2003-11-21 2005-12-28 Novartis Ag Derivados de 1h-imidazo[4,5-c]quinolina para tratamiento de enfermedades dependientes de las proteino-quinasas
JP2007511575A (ja) * 2003-11-21 2007-05-10 ノバルティス アクチエンゲゼルシャフト タンパク質キナーゼ阻害剤としての１ｈ−イミダゾキノリン誘導体
US8697873B2 (en) 2004-03-24 2014-04-15 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
CA2597446A1 (en) 2005-02-11 2006-08-31 Coley Pharmaceutical Group, Inc. Substituted imidazoquinolines and imidazonaphthyridines
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
WO2007035935A1 (en) 2005-09-23 2007-03-29 Coley Pharmaceutical Group, Inc. METHOD FOR 1H-IMIDAZO[4,5-c]PYRIDINES AND ANALOGS THEREOF
CN101330916A (zh) 2005-12-16 2008-12-24 科勒制药集团公司 经取代的咪唑并喹啉、咪唑并萘啶和咪唑并吡啶、其组合物及其方法
WO2007079086A1 (en) 2005-12-28 2007-07-12 Coley Pharmaceutical Group, Inc. Pyrazoloalkyl substituted imidazo ring compounds and methods
RU2478387C2 (ru) 2007-02-20 2013-04-10 Новартис Аг ИМИДАЗОХИНОЛИНЫ В КАЧЕСТВЕ ДВОЙНЫХ ИНГИБИТОРОВ ЛИПИДКИНАЗЫ И mTOR
WO2010003025A1 (en) 2008-07-01 2010-01-07 Genentech, Inc. Bicyclic heterocycles as mek kinase inhibitors
CA2729914A1 (en) 2008-07-11 2010-01-14 Novartis Ag Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) a modulator of ras/raf/mek pathway
WO2010038165A1 (en) * 2008-09-30 2010-04-08 Pfizer Inc. Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions
MY156209A (en) 2009-11-04 2016-01-29 Novartis Ag Heterocyclic sulfonamide derivatives useful mek inhibitors
JP5863058B2 (ja) * 2010-05-17 2016-02-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング １Ｈ−イミダゾ［４，５−ｃ］キノリン
TW201204725A (en) 2010-07-16 2012-02-01 Piramal Lifesciences Ltd Substituted imidazoquinoline derivatives as kinase inhibitors
US9181264B2 (en) 2010-09-16 2015-11-10 Hutchison Medipharma Limited Fused heteroaryls and their uses
KR20140014104A (ko) * 2010-12-06 2014-02-05 피라말 엔터프라이지즈 리미티드 치환된 이미다조퀴놀린 유도체
CA2850932A1 (en) 2011-10-04 2013-04-11 Janus Biotherapeutics, Inc. Novel imidazole quinoline-based immune system modulators
GB201205669D0 (en) 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
KR20150013332A (ko) 2012-05-31 2015-02-04 바이엘 파마 악티엔게젤샤프트 간세포 암종(hcc) 환자 치료제의 효과적 반응을 결정하기 위한 바이오마커
WO2015022664A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
WO2015022663A1 (en) 2013-08-14 2015-02-19 Novartis Ag Compounds and compositions as inhibitors of mek
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK

Also Published As

Publication number Publication date
US9227969B2 (en) 2016-01-05
TW201536782A (zh) 2015-10-01
US10011599B2 (en) 2018-07-03
JP6473453B2 (ja) 2019-02-20
EP3033343A1 (en) 2016-06-22
IL243349A0 (en) 2016-02-29
GEP201706725B (en) 2017-08-25
TR201902709T4 (tr) 2019-03-21
MX359401B (es) 2018-09-27
EP3033343B1 (en) 2018-12-05
PT3033343T (pt) 2019-03-21
AU2014307593B2 (en) 2016-07-21
HK1219271A1 (zh) 2017-03-31
PE20160204A1 (es) 2016-04-27
US20150051209A1 (en) 2015-02-19
SV2016005153A (es) 2016-11-21
ES2714718T3 (es) 2019-05-29
CR20160072A (es) 2016-05-09
CA2921300A1 (en) 2015-02-19
JP2016530263A (ja) 2016-09-29
PH12016500003A1 (en) 2016-03-28
UA116566C2 (uk) 2018-04-10
AU2014307593A1 (en) 2016-02-04
EA201690386A1 (ru) 2016-06-30
BR112016001783B1 (pt) 2022-07-05
AU2014307593C1 (en) 2016-11-24
MX2016001980A (es) 2016-06-21
PL3033343T3 (pl) 2019-06-28
CN105473588A (zh) 2016-04-06
US20160136150A1 (en) 2016-05-19
TN2015000574A1 (en) 2017-04-06
KR20160039203A (ko) 2016-04-08
CN105473588B (zh) 2018-06-05
NI201600014A (es) 2016-03-10
WO2015022662A1 (en) 2015-02-19
CA2921300C (en) 2021-06-29
US20170183348A1 (en) 2017-06-29
AP2016008981A0 (en) 2016-01-31
CL2016000150A1 (es) 2016-06-10
CU20160020A7 (es) 2017-02-02
US9629836B2 (en) 2017-04-25
BR112016001783A2 (pt) 2017-08-01
KR102354208B1 (ko) 2022-01-20
EA029093B1 (ru) 2018-02-28
ZA201509337B (en) 2017-04-26
SG11201510727VA (en) 2016-02-26
UY35704A (es) 2015-03-27

Similar Documents

Publication Publication Date Title
SV2016005153A (es) Compuestos y composiciones como inhibidores de la mek
GT201400196A (es) Compuestos de heterociclilo
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
MX2015012456A (es) Compuestos heterociclicos y usos de los mismos.
MX2019006739A (es) Esteroides neuroactivos sustituidos con 19-alcoxi-17, profarmacos de los mismos, y metodos de tratamiento usando los mismos.
CR20150370A (es) Compuestos antivirales
BR112015022191A2 (pt) compostos heteroarila, seu uso e composição que os compreende
CL2015003801A1 (es) Formulaciones de anticuerpos y metodos
MX2022001697A (es) Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos.
CR20160272A (es) REGULADORES DE Nrf2
MX388137B (es) Formulaciones eutecticas de clorhidrato de ciclobenzaprina y de clorhidrato de amitriptilina.
MX386584B (es) Composiciones de liberación retardada de linaclotida.
CU20140095A7 (es) Nuevos derivados fosfatos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
ECSP15013883A (es) Benzamidas
UY36224A (es) Compuestos tricíclicos de imidazo-pirimidinona
BR112017002214A2 (pt) composto de fórmula (i), composição farmacêutica e usos de um composto
DOP2018000062A (es) Piridinona dicaboxamidas para uso como inhibidores de bromodominio
UY37015A (es) Inhibidores de la tirosina quinasa de bruton y métodos de su uso
ECSP16062173A (es) Derivados de ácido heteroaril butanóico como inhibidores de lta4h
NI201500096A (es) Compuesto químicos
MX2018007084A (es) Inhibidores de la tirosina quinasa de bruton y metodos de su uso.
GT201400007A (es) Sales de éteres aza bicíclicos de di-arilo y métodos para preparar los mismos o sus precursores
AR095353A1 (es) Compuesto
BR112015030589A8 (pt) formas polimórficas de fosfato de icotinibe, composição farmacêutica compreendendo as referidas formas e usos das mesmas
CU20160019A7 (es) Polimorfo de inhibidores de tirosina quinasa del bazo (syk), métodos de prepración y composiciones